Can extra immunotherapy stall advanced lung cancer?
NCT ID NCT06219317
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether continuing the immunotherapy drug cemiplimab for up to a year after initial treatment can delay cancer growth in people with stage IV non-small cell lung cancer that has spread to only a few places (oligometastatic). About 136 participants will be randomly assigned to receive either cemiplimab or a placebo. The study aims to see if the drug improves progression-free survival compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab (an immunotherapy drug)
What this could lead to
If successful, this could show that continuing immunotherapy after initial treatment helps keep advanced lung cancer from growing for longer.
What could go wrong
This is a phase 2 trial with only 136 people, so results may not apply to everyone. Immunotherapy can cause immune-related side effects like inflammation in organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AUSL Della Romagna - Ospedale Santa Maria delle Croci
Ravenna, Italy
-
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
-
Azienda Ospedaliero - Universitaria "Santa Maria della Misericordia" di Udine
Udine, Italy
-
Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital
Legnano, Italy
-
CH de La Cote Basque - Saint Leon
Bayonne, France
-
CHU Helora Pole Hospitalier Jolimont
Haine-Saint-Paul, Belgium
-
CHU Mont Godinne - UCL Namur
Yvoir, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Institut Paoli-Calmettes
Marseille, France
-
UOMi Cancer Center
Barcelona, Spain
-
University Hospital Virgen del Rocio
Seville, Spain